A re-appraisal of Warfarin control in the treatment of Deep Vein Thrombosis and / or Pulmonary Embolism

African Health Sciences

Volumn 9, Issue 3, 2009, Pages 179-185

  Amiwero, C ^a   Campbell, I A ^b   Prescott, R J ^c  

^a FEDERAL MEDICAL CENTER   (Nigeria)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Deep vein thrombosis; Haemorrhage; International normalized ratio; Pulmonary embolism; Thromboembolism; Warfarin

Indexed keywords

WARFARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RECURRENCE; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN; YOUNG ADULT;

EID: 77949516187     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91(4):472-7.
2. Lopez JA, Kearon C, Lee YYA. Deep Venous Thrombosis. Haematology 2004; 1: 439.
3. Jackson MC, Esnouf PM, Lindahl T. A Critical Evaluation of the Prothrombin Time for Monitoring Oral Anticoagulant Therapy. Pathophysiol Haemost Thromb 2003; 33:43-51. Available at http://www.karger.com/pht.
4. Hollowell J, Ruigomez A, Johansson S, Wallander M, Garcia-Rodriquez LA. The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Brit J of Gen Pract 2003; 53:312-314
5. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, Prediction and Prevention. Am J Med 1993; 95:315-28.
6. th edition, ed by Hoffbrand, V.A., Lewis, S.M., Tuddenham, E.G.D.2001; pp 653-72.
7. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
8. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Bueton E, Anderson D. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003; 169 (4). Available at http://www.cmaj.ca/cgi/content/full/169/4/293.
9. Fang MC, Chang V, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced Age, Anticoagulation intensity, and Risk for intracranial Haemorrhage among Patients Taking Warfarin for fibrillation. Ann intern Med 2004; 141:745-752.
10. Barclay L, Vega C. Lower Targets for Warfarin Therapy May Be Better. Arch Inter Med 2004; 164:588-590, 668-673.
11. Berwaerts J, Webster J. Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages. Q J Med 2000; 93: 513-521.
12. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HGM, Williamson IJ for the Research Committee of the British Thoracic Society. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ. 2007; doi:10.1136/bmj.39098.583356.55